Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis

NCT07012395 is registered in ClinicalTrials.gov with Spyre Therapeutics, Inc. as lead sponsor.

NCT NCT07012395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07012395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Spyre Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
May 27, 2025
Completion date
March 31, 2028
Enrollment
645 (estimated)
Sites
273

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, colitis, ulcerative, inflammatory bowel diseases, ulcerative colitis